Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: van der Velden, Jan Willem; ; ; | Jaquenoud Sirot, Eveline
Affiliations: Global Safety and Pharmacovigilance PharmaNet AG, Küsnacht, Switzerland | Postgraduate Programme in Pharmaceutical Medicine, Université Libre de Bruxelles, Belgium | Psychiatrische Dienste Aargau AG, MediQ, Klinik Königsfelden, Brugg, Switzerland
Note: [] Corresponding author: J.W. van der Velden, MD, FFPM, FISPE, Senior Vice President of Global Safety and Pharmacovigilance, PharmaNet AG, Obere Wiltigasse 52, CH-8700 Küsnacht, Switzerland. E-mail: [email protected]
Note: [] Jan Willem van der Velden has disclosed that he is an employee of PharmaNet. Eveline Jaquenoud Sirot reports no relationships to disclose.
Abstract: Risk management proactively assesses the potential risks and benefits of health care interventions, including both drugs and medical devices. Risk management systematically identifies safety indications and establishes a risk management strategy for potential adverse events. Professionals trained in risk management have unique expertise in assessing the balance between risk and benefit. They play an important role in clinical study oversight (pre- and postmarketing) and in measuring outcomes of health care interventions. Assessing the risks and benefits of any therapy requires consideration of the complex interactions of multiple variables of the population to treat, including disease state, proposed treatment, and potential risks. Several key factors contribute to the effectiveness and acceptability of any treatment. For example, physician compliance with prescribing guidelines and a patient's ability to tolerate a drug and to understand how to administer medications accurately will affect risk management assessments. Concurrent treatments (drug interactions) and diseases are also important considerations. Other variables include drug treatment ratios (placebo/active) and, increasingly, the use of screening tools to identify pharmacogenetic markers in particular patient populations that correlate with drug metabolism, efficacy, and other outcomes.
Journal: International Journal of Risk and Safety in Medicine, vol. 19, no. 3, pp. 145-151, 2007
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]